Summary:
Orange County Research Center is conducting a randomized, Double-Blind, Parallel Group Study to assess Cardiovascular Outcomes following treatment with Ertugliflozin in subjects with Type 2 Diabetes Mellitus and established Vascular Disease.
Qualified Participants Must:
• Be 40 years of age or older
•
Have Type 2 Diabetes
•
Have a HbA1c at Screening of 7% or higher
•
Have evidence of history of atherosclerosis involving coronary, cerebral, or peripheral vascular systems. (X: Coronary Artery Disease (CAD) Peripheral Artery Disease (PAD) Heart Attack, Stroke, Revascularization, CABG, etc.)
Qualified Participants May Receive:
Compensation for time and travel, up to: $1050.00